Almost 36,000 people in the state are believed to have been treated with convalescent plasma by two Covid waves. The Pune sector was the most used, followed by Nagpur and Concan.
In the CONCOR-1 trial published in the Nature Medicine journal, plasma therapy, one of the most hyped treatments, was ineffective in reducing the risk of intubation (using a ventilator) or death. understood. To make matters worse, blood product recipients (33%) had significantly more serious adverse events such as increased oxygen requirements and respiratory failure than those who received standard care (26.4%). There were many. Intubation or death occurred in 32.4% of patients treated with plasma, and more than 28% did not receive plasma.
Another important lesson was that fluctuating antibody levels in patients and plasma donors influence therapeutic response. “If plasma antibody levels are found to be low or non-functional, there is an increased risk of intubation or death,” the study found. Researchers believed that “poor” antibodies in plasma might compete with the patient’s functioning antibodies to disrupt the immune response.
“Plasma in Covid-19 survivors has been thought to help people who are seriously ill due to the virus, but unfortunately it is not,” said a professor and co-principal investigator at McMaster University in Canada. Donald Arnold told PTI.
The demand for plasma touched the sky during the first wave as the patient bombarded up to 60,000 rupees in a single unit. The euphoria subsided when the Indian Medical Research Council (ICMR) revealed last year that plasma was not very effective. However, it did not disappear as the private sector continued to use it indiscriminately. ICMR removed it from the treatment protocol only in May this year.
Maharashtra has announced the Platina project, a unique study of plasma distribution for 150 critical patients and emergency use. Node Officer Dr. Mohammed Faisal said it was discontinued in January because it turned out to be harmful, adding that the findings will be published.
According to the Maharashtra FDA, 34,874 units of plasma were distributed throughout the district. A total of 19,631 people donated 36,246 bags of plasma. They stopped keeping records because the ICMR removed it from the treatment protocol, officials said. The state does not have data on deaths caused by plasma adverse events.
Dr. Vasant Nagvekar, a member of the state’s Covid task force, said plasma use for monoclonal antibodies has almost stopped.
Research, Health News, ET HealthWorld
Source link Research, Health News, ET HealthWorld